SWISS TXT subtitling 1000 videos in 4 languages for Play Suisse
plus
Actualités de Lausanne
Bram Goorden joins SOPHiA GENETICS as Chief Commercial Officer and Head of North America
Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Bram Goorden joined its Executive team, holding the dual role of Chief Commercial Officer and Head of North America. Goorden comes to SOPHiA from Foundation Medicine Inc. (Cambridge, MA) where he held the role of VP of International Business and ...
plusFirmenich Launches World's First AI-Augmented Laundry Care Fragrances
Geneva (ots/PRNewswire) - Firmenich, the world's largest privately owned fragrance and taste company, has introduced the industry's first laundry care fragrances that fuse Artificial Intelligence (AI) with human creativity. Presented at a customer Sensorium(TM) in Hangzhou, China during the China Cleaning Industry Association (CCIA) conference, the AI-augmented ...
plusDebiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...
plusDEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER
Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...
plusSOPHiA GENETICS Raises $110 Million in Oversubscribed New Funding Round
Lausanne, Switzerland and Boston (ots/PRNewswire) - Supporting the Company's Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company ...
plus
DEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
plusDEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Un documentplusEuro Airport Basel-Mulhouse-Freiburg
3From 25 nights to just 4 hours: EuroAirport introduces a breakthrough runway survey technology
Un documentplusBelgian scale-up Oncomfort raises EUR10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop its Digital SedationTM through Virtual Reality
plusDEBIOPHARM'S NEW GENERATION RADIONUCLIDE THERAPY ADVANCES INTO CLINICAL RESEARCH IN THE FIGHT AGAINST LUNG CANCER
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
plusDEBIOPHARM'S IAP ANTAGONIST SIGNIFICANTLY IMPROVES OVERALL SURVIVAL OF HIGH-RISK HEAD & NECK CANCER PATIENTS
Lausanne, Switzerland (ots) - Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of ...
plus
Schweizerischer Nationalfonds / Fonds national suisse
28 new coronavirus research projects funded under NRP "COVID-19"
Bern (ots) - New research has been launched to better control COVID-19. 18.6 million francs have been invested in projects that will investigate innovative solutions and develop public health recommendations. Mandated by the Federal Council, the SNSF launched the National Research Programme "COVID-19" (NRP 78) on 30 April 2020 to advance our understanding of the ...
plusNUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM
Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...
plusEuroclear Holding, Euroclear Investments, Euroclear SA/NV
Euroclear: Directorate Changes
Brussels (ots/PRNewswire) - The Euroclear group announces that Marc Antoine Autheman has decided to step down as the Chairman and Director of the Euroclear boards. During Mr Autheman's eight year tenure, Euroclear's strategy has resulted in its strong financial position and performance, delivering consistently growing returns for shareholders and value for its financial market participants, whilst adapting to meet the requirements of the post-financial crisis regulatory and ...
plusGalderma Global Research Reveals Struggles of People With Rosacea and Psoriasis of the Face Experiencing a Lack of Control and Impact on Mental Wellbeing
Lausanne, Switzerland (ots/PRNewswire) - Healthcare professionals (HCPs) encouraged to investigate true impacts beyond the visible, empower patients with knowledge and aim for 'clear' (IGA 0) skin to improve outcomes A new expert-authored Galderma report (https://hosted.bmj.com/rosaceabeyondthevisible) released ...
plusDebiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
Lausanne, Switzerland (ots) - Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program, to treat diseases related to dysbiosis of the human gut microbiome Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement ...
plusAcquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention
Lausanne, Switzerland (ots) - - Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience - Kaiku's acquisition by the Swedish company Elekta allows thousands of cancer treatment centers to gain access to the ...
plus
Schweizerischer Nationalfonds / Fonds national suisse
The SNSF funds 36 new coronavirus research projects
Bern (ots) - Under the special call on coronaviruses, the societal and biomedical aspects of epidemics will be investigated with a total budget of 10 million francs. The projects will start as of 1 June 2020. As the coronavirus pandemic began to take hold, the SNSF took swift action by launching a special call on coronaviruses on 6 March 2020. The call was enthusiastically received in the research community. - ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Imaging science
Bern (ots) - Spectacular photographs, provocative videos and intimate stories shed new light on contemporary research. The jury for this year's SNSF Scientific Image Competition has awarded four first prizes and seven distinctions. The fourth SNSF Scientific Image Competition has been a great success. "These stunning images offer a view of science that is very different from the usual clichés of white coats, antiseptic laboratories and faceless researchers", says Nadine ...
plusSOPHiA GENETICS Expands Its Executive Team, Naming Lara Hashimoto Chief Business Officer
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be responsible for Marketing, Product Management and Business Development. Lara Hashimoto joined the healthcare industry 20 years ago holding ...
plusSOPHiA GENETICS and Paragon Genomics Join Forces Against the COVID-19 Coronavirus Pandemic
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, today announced that it is entering the fight against the COVID-19 coronavirus by extending its partnership with Paragon Genomics, who developed a next-generation sequencing (NGS) assay and leveraging the SOPHiA Platform analytical capabilities, as well as delivering ...
plusSOPHiA GENETICS' Board of Directors Elects Troy Cox as New Chairman
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors, effective March 1, 2020. He is replacing Antoine Duchateau, who has served as chairman since 2013 and will continue as a board member. Cox joined the ...
plusNovadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million
Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...
plus
Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...
plusSchweizerischer Nationalfonds / Fonds national suisse
The 2020 SNSF Scientific Image Competition is underway
Bern (ots) - Capturing the beauty of science: the Swiss National Science Foundation is once again holding its photo and short video competition in 2020. Nadine Wietlisbach, director of the Fotomuseum Winterthur, will chair the jury. The images will be exhibited for the first time at the Biel/Bienne Photography Festival in May and will be freely available to the public and the media. The 2020 edition of the SNSF Scientific ...
plusFace Up To Rosacea: Galderma Launches Online Support to Empower and Equip Rosacea Sufferers to Discuss the True Burden of Their Disease With a Dermatologist
New 'Face up to rosacea' campaign comprising online content and a downloadable, personalized patient appointment guide, equips people living with the distressing skin disease to seek expert support to help break the cycle of rosacea and aim for long-term treatment success Lausanne, Switzerland (ots/PRNewswire) - ...
plusChangemakers from over 46 countries met in Zermatt / 8th Zermatt Summit 2019 - Humanizing Globalization - Entrepreneurship to serve the common good
plusA pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
plusSOPHiA GENETICS Expands Executive Team With a Chief Marketing Officer and New Chief Information Officer
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly ...
plus
Précédent12345678Suivant